Business Wire

TII

13.5.2024 15:37:31 CEST | Business Wire | Press release

Share
Falcon 2: UAE’s Technology Innovation Institute Releases New AI Model Series, Outperforming Meta’s New Llama 3

The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today launched a second iteration of its renowned large language model (LLM) – Falcon 2. Within this series, it has unveiled two groundbreaking versions: Falcon 2 11B, a more efficient and accessible LLM trained on 5.5 trillion tokens with 11 billion parameters, and Falcon 2 11B VLM, distinguished by its vision-to-language model (VLM) capabilities, which enable seamless conversion of visual inputs into textual outputs. While both models are multilingual, notably, Falcon 2 11B VLM stands out as TII's first multimodal model – and the only one currently in the top tier market that has this image-to-text conversion capability, marking a significant advancement in AI innovation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513516248/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Falcon Image Caption Generator (Photo: AETOSWire)

Tested against several prominent AI models in its class among pre-trained models, Falcon 2 11B surpasses the performance of Meta’s newly launched Llama 3 with 8 billion parameters (8B), and performs on par with Google’s Gemma 7B at first place (Falcon 2 11B: 64.28 vs Gemma 7B: 64.29), as independently verified by Hugging Face, a US-based platform hosting an objective evaluation tool and global leaderboard for open LLMs. More importantly, Falcon 2 11B and 11B VLM are both open-source, empowering developers worldwide with unrestricted access. In the near future, there are plans to broaden the Falcon 2 next-generation models, introducing a range of sizes. These models will be further enhanced with advanced machine learning capabilities like 'Mixture of Experts' (MoE), aimed at pushing their performance to even more sophisticated levels.

All of TII’s AI models released to date have consistently ranked in the top tier globally, as the most powerful open-source LLMs. The new scaled-down and versatile Falcon 2 11B models are set to give TII greater market adoption in the ever-evolving world of generative AI.

Falcon 2 11B models, equipped with multilingual capabilities, seamlessly tackle tasks in English, French, Spanish, German, Portuguese, and various other languages, enriching their versatility and magnifying their effectiveness across diverse scenarios. Falcon 2 11B VLM, a vision-to-language model, has the capability to identify and interpret images and visuals from the environment, providing a wide range of applications across industries such as healthcare, finance, e-commerce, education, and legal sectors. These applications range from document management, digital archiving, and context indexing to supporting individuals with visual impairments. Furthermore, these models can run efficiently on just one graphics processing unit (GPU), making them highly scalable, and easy to deploy and integrate into lighter infrastructures like laptops and other devices.

H.E. Faisal Al Bannai, Secretary General of ATRC and Strategic Research and Advanced Technology Affairs Advisor to the UAE President, said: "With the release of Falcon 2 11B, we've introduced the first model in the Falcon 2 series. While Falcon 2 11B has demonstrated outstanding performance, we reaffirm our commitment to the open-source movement with it, and to the Falcon Foundation. With other multimodal models soon coming to the market in various sizes, our aim is to ensure that developers and entities that value their privacy have access to one of the best AI models to enable their AI journey."

Speaking on the model, Dr. Hakim Hacid, Executive Director and Acting Chief Researcher of the AI Cross-Center Unit at TII, said: “AI is continually evolving, and developers are recognizing the myriad benefits of smaller, more efficient models. In addition to reducing computing power requirements and meeting sustainability criteria, these models offer enhanced flexibility, seamlessly integrating into edge AI infrastructure, the next emerging megatrend. Furthermore, the vision-to-language capabilities of Falcon 2 open new horizons for accessibility in AI, empowering users with transformative image to text interactions.”

The versatility of Falcon 2 11B has also led TII to consider working on more exciting GenAI innovations. Among these will be the adoption of a new type of machine learning capability known as the aforementioned ‘Mixture of Experts’. This method involves amalgamating smaller networks with distinct specializations, ensuring that the most knowledgeable domains collaborate to deliver highly sophisticated and customized responses – almost like having a team of smart helpers who each know something different and work together to predict or make decisions when needed. This approach not only improves accuracy, but it also accelerates decision-making, paving the way for more intelligent and efficient AI systems.

Falcon 2 11B is licenced under TII Falcon License 2.0, the permissive Apache 2.0-based software license which includes an acceptable use policy that promotes the responsible use of AI. More information on the new model can be found at FalconLLM.TII.ae.

Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513516248/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye